Media stories about ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) have been trending somewhat positive on Saturday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ESSA Pharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.1109756882092 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several equities analysts have weighed in on EPIX shares. Dawson James restated a “buy” rating on shares of ESSA Pharma in a report on Thursday, August 3rd. Zacks Investment Research cut ESSA Pharma from a “hold” rating to a “sell” rating in a report on Thursday, May 18th. Bloom Burton reiterated a “buy” rating on shares of ESSA Pharma in a report on Thursday, May 18th. Finally, ValuEngine cut ESSA Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $9.00.
Shares of ESSA Pharma (NASDAQ:EPIX) traded up 2.86% during trading on Friday, hitting $0.36. The stock had a trading volume of 6,126 shares. The firm’s 50-day moving average is $0.42 and its 200 day moving average is $1.67. The firm’s market cap is $10.47 million. ESSA Pharma has a 52-week low of $0.25 and a 52-week high of $3.59.
ILLEGAL ACTIVITY NOTICE: “ESSA Pharma (EPIX) Earning Somewhat Positive News Coverage, Study Shows” was reported by Zolmax and is the sole property of of Zolmax. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://zolmax.com/investing/essa-pharma-epix-earning-somewhat-positive-news-coverage-study-shows/1560284.html.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/essa-pharma-epix-earning-somewhat-positive-news-coverage-study-shows/1560284.html
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.